AlphaStocks
5.7
Consider Buy

Johnson & Johnson (JNJ)

As of Sep 20, 2026, Johnson & Johnson (JNJ) scores 5.7/10 on AlphaStocks' five-model composite, #67 of 168 Health Care stocks. At $270, JNJ trades 13% below its model fair value of $311.

Health Care / Pharmaceuticals

S&P 500

$269.93

Middle of the pack. No strong signal either way.

Consider Buy

Score based on 5 of 5 models — high confidence

Data as of Sep 20, 2026

#67out of 168 in Health Care

Is JOHNSON & JOHNSON a Good Investment in 2026?

JOHNSON & JOHNSON (JNJ) scores 5.7 out of 10 on AlphaStocks' composite model, earning a Consider Buy rating. The Buffett model rates JOHNSON & JOHNSON as Attractive. However, the Graham model rates it Caution — Significantly above fair value. JOHNSON & JOHNSON currently trades 13% below its estimated fair value of $311. JOHNSON & JOHNSON ranks #67 out of 168 stocks in the Health Care sector.

This summary is algorithmically generated and is not financial advice.

Key Metrics

P/E24.5ROE33.3Market Cap660BDiv Yield2.0

Estimated Fair Value

$311.4513% below

Trading below estimated fair value. EPS grew 91% year-over-year. ROE of 33% signals strong profitability. P/E of 24x is moderate for this quality level.

Model-based estimate, not a price target.

5-Model Analysis

Each model evaluates this stock from a different angle. Combined, they form the composite score above.

Piotroski

Neutral

4/9

Buffett

Attractive

Business quality & competitive moat

Graham

Caution

Significantly above fair value

Lynch

Neutral

High PEG — growth premium · Slow Grower

Greenblatt

Neutral

Earnings yield 3.9% · ROC >100%

Frequently Asked Questions

Is JOHNSON & JOHNSON (JNJ) a good investment?
As of Sep 20, 2026, Johnson & Johnson (JNJ) scores 5.7/10 on AlphaStocks' five-model composite, #67 of 168 Health Care stocks. At $270, JNJ trades 13% below its model fair value of $311. That is a middle-of-the-pack score with no strong signal either way.
What is JOHNSON & JOHNSON's Piotroski F-Score?
JOHNSON & JOHNSON's Piotroski F-Score status is Neutral. The raw score is 4/9. The Piotroski F-Score evaluates financial health using 9 fundamental signals including profitability, leverage, and operating efficiency.
Is JNJ overvalued or undervalued?
Based on AlphaStocks' model-based fair value estimate of $311, JNJ appears undervalued. The stock currently trades 13% below its estimated fair value. Trading below estimated fair value. EPS grew 91% year-over-year. ROE of 33% signals strong profitability. P/E of 24x is moderate for this quality level.
How does JNJ compare to other Health Care stocks?
JOHNSON & JOHNSON ranks #67 out of 168 stocks in the Health Care sector, placing it in the top 40% of its sector by composite score. This is an above-average position relative to sector peers.
What do investment models say about JNJ?
AlphaStocks evaluates JNJ using five proven investment models. Piotroski: Neutral; Buffett: Attractive; Graham: Caution; Lynch: Neutral; Greenblatt Magic Formula: Neutral. These models are combined into a single composite score of 5.7/10.

Similar Stocks

AMPHLLYACAD

Compare JNJ with

AMPH vs JNJJNJ vs LLYACAD vs JNJJNJ vs PARR

Scores are algorithm-generated research tools, not investment recommendations. Past performance does not guarantee future results. Always do your own due diligence. Full disclaimer